# The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

> **NCT07247656** · PHASE4 · COMPLETED · sponsor: **Bahria University** · enrollment: 200 (actual)

## Conditions studied

- Diabete Mellitus

## Interventions

- **DRUG:** (Empagliflozin 10 mg+ Tab Linagliptin 5mg)
- **DRUG:** Tab Empagliflozin 10 mg + Tab Metformin 500 mg

## Key facts

- **NCT ID:** NCT07247656
- **Lead sponsor:** Bahria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247656, "The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07247656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*